Business
Hofseth BioCare ASA: Publication of the Prospectus – Start of the Subscription Period for the Subsequent Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private
About this update from Hofseth Biocare Asa
[{"type":"image","alt":"Hofseth Biocare ASA","displaySize":"","headline":null,"caption":"Hofseth Biocare ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/e6eeab71f70356cc48046edfaa6b96f2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d3X3Kf.TCy_ExyT_flroVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6eeab71f70356cc48046edfaa6b96f2","width":300,"height":89}},"lazy":false},{"type":"text","content":"NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.","length":321,"tagName":"p"},{"type":"text","content":"Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares in the Company, and to the stock exchange announcement on 7 November 2025 regarding the terms and conditions for a subsequent offering of up to 16,666,666 new Ordinary Shares in the Company (the "Offer Shares"), each at the same subscription price per Offer Share as the subscription price in the Private Placement (the "Subsequent Offering").","length":597,"tagName":"p"},{"type":"text","content":"The Company has prepared a national prospectus (Nw: nasjonalt prospekt (the "Prospectus") in accordance with the rules in the Norwegian Securities Trading Act chapter 7. The Prospectus has now been registered with the Norwegian Register of Business Enterprises and has been made available at the websites of the Company (https://hofsethbiocare.com). The Prospectus is a national prospectus (Nw: nasjonalt prospekt) and neither the Norwegian Financial Supervisory Authority nor any other public authority has carried out any form of review, control or approval of the Prospectus.","length":588,"tagName":"p"},{"type":"text","content":"The subscription period in the Subsequent Offering commences today, 10 November 2025, at 09:00 (CET) and ends on 20 November 2025 at 16:30 (CET).","length":145,"tagName...